MX2021009413A - Materiales y métodos para tratar una enfermedad neurodegenerativa. - Google Patents
Materiales y métodos para tratar una enfermedad neurodegenerativa.Info
- Publication number
- MX2021009413A MX2021009413A MX2021009413A MX2021009413A MX2021009413A MX 2021009413 A MX2021009413 A MX 2021009413A MX 2021009413 A MX2021009413 A MX 2021009413A MX 2021009413 A MX2021009413 A MX 2021009413A MX 2021009413 A MX2021009413 A MX 2021009413A
- Authority
- MX
- Mexico
- Prior art keywords
- materials
- methods
- treat
- neurodegenerative disease
- kaempferol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801271P | 2019-02-05 | 2019-02-05 | |
| PCT/US2020/016820 WO2020163493A2 (en) | 2019-02-05 | 2020-02-05 | Materials and methods for treating a neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009413A true MX2021009413A (es) | 2022-01-18 |
Family
ID=71947875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009413A MX2021009413A (es) | 2019-02-05 | 2020-02-05 | Materiales y métodos para tratar una enfermedad neurodegenerativa. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220401404A1 (https=) |
| EP (1) | EP3930711A4 (https=) |
| JP (1) | JP2022523919A (https=) |
| CN (1) | CN114007607A (https=) |
| AU (1) | AU2020219140A1 (https=) |
| BR (1) | BR112021015466A2 (https=) |
| CA (1) | CA3129050A1 (https=) |
| MX (1) | MX2021009413A (https=) |
| WO (1) | WO2020163493A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021022270A2 (pt) * | 2019-05-06 | 2022-01-11 | Univ California | Materiais e métodos para tratar degeneração macular relacionada à idade |
| CN115429788B (zh) * | 2022-10-24 | 2023-11-21 | 上海中医药大学附属岳阳中西医结合医院 | 一种治疗脱髓鞘疾病的药物及应用 |
| CN119454686A (zh) * | 2024-08-06 | 2025-02-18 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 山柰酚或含有山柰酚的组合物在制备治疗和/或缓解多发性硬化症药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1850840A2 (en) | 2005-01-13 | 2007-11-07 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| WO2009147009A2 (en) * | 2008-06-06 | 2009-12-10 | Nicox S.A. | Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug |
| US20130252924A1 (en) * | 2010-11-11 | 2013-09-26 | Akron Molecules Gmbh | Compounds and Methods for Treating Pain |
| WO2013049621A1 (en) * | 2011-09-29 | 2013-04-04 | The Board Of Regents Of The University Of Oklahoma | Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof |
| CN105636582A (zh) * | 2013-09-18 | 2016-06-01 | 乔治城大学 | 用非诺贝特及其类似物治疗神经退行性疾病 |
| CN109069450A (zh) * | 2016-02-05 | 2018-12-21 | 法奈克斯公司 | 神经障碍的新的组合疗法 |
-
2020
- 2020-02-05 JP JP2021545944A patent/JP2022523919A/ja active Pending
- 2020-02-05 WO PCT/US2020/016820 patent/WO2020163493A2/en not_active Ceased
- 2020-02-05 BR BR112021015466-3A patent/BR112021015466A2/pt not_active IP Right Cessation
- 2020-02-05 CN CN202080027379.9A patent/CN114007607A/zh active Pending
- 2020-02-05 US US17/428,867 patent/US20220401404A1/en not_active Abandoned
- 2020-02-05 CA CA3129050A patent/CA3129050A1/en active Pending
- 2020-02-05 MX MX2021009413A patent/MX2021009413A/es unknown
- 2020-02-05 EP EP20753139.3A patent/EP3930711A4/en not_active Withdrawn
- 2020-02-05 AU AU2020219140A patent/AU2020219140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020163493A2 (en) | 2020-08-13 |
| WO2020163493A9 (en) | 2020-11-19 |
| US20220401404A1 (en) | 2022-12-22 |
| EP3930711A4 (en) | 2023-01-11 |
| BR112021015466A2 (pt) | 2021-10-19 |
| JP2022523919A (ja) | 2022-04-27 |
| CN114007607A (zh) | 2022-02-01 |
| EP3930711A2 (en) | 2022-01-05 |
| CA3129050A1 (en) | 2020-08-13 |
| WO2020163493A3 (en) | 2020-10-22 |
| AU2020219140A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001575A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| CL2017001117A1 (es) | Métodos para tratar enfermedades oculares. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| CO2019007205A2 (es) | Usos terapéuticos de un polvo de insectos | |
| CO2020000260A2 (es) | Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide | |
| MX2021000340A (es) | Nuevos compuestos. | |
| CY1122746T1 (el) | Ιατρικες αγωγες με βαση την αναμορελινη | |
| MX392470B (es) | Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica. | |
| MX2021012894A (es) | Compuestos ciclicos de fosfato. | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| MX2021009413A (es) | Materiales y métodos para tratar una enfermedad neurodegenerativa. | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| EP3685840A4 (en) | PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX2018014915A (es) | Tratamiento de enfermedades colestasicas intrahepaticas. | |
| CO2019003865A2 (es) | Proteína terapéutica | |
| EP3517121A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PURPLE CORN FOR THE PREVENTION OR TREATMENT OF A SKIN DISEASE | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
| MX2021013609A (es) | Materiales y métodos para tratar la degeneración macular relacionada con la edad. | |
| AR109693A1 (es) | Formulaciones de liberación inmediata de oprozomib | |
| MX2019006886A (es) | Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2). | |
| MX2017006063A (es) | Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal. |